Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Huaming Tan, Hernan Valdez, Christopher Griffiths, Ulrich Mrowietz, Anna Tallman, Robert Wolk, Kenneth Gordon

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The ability to predict response to psoriasis treatments has important implications. Tofacitinib is an oral JAK inhibitor being investigated for psoriasis.

OBJECTIVE: The objective of this study is to identify and validate the clinical predictors of responses in psoriasis patients treated with tofacitinib.

METHODS: Selected baseline characteristics or early improvement in Psoriasis Area and Severity Index (PASI) in the phase 3 tofacitinib study OPT 1 (NCT01276639) were evaluated as predictors for a clinical response (75% improvement in PASI [PASI75]) at week 16. Predictive ability was assessed by the area-under-the-receiver operating characteristic curve (AUC-ROC). The predictive ability of the identified variables was validated with study OPT 2 (NCT01309737).

RESULTS: PASI improvement at weeks 8 and 12 demonstrated good discriminatory abilities to predict PASI75 response at week 16 (AUC-ROC ≥86% and 94%, respectively) in OPT 1. Validation with PASI50 response at week 8 in OPT 2 to predict PASI75 response at week 16 showed that the sensitivity, specificity, PPV, and NPV were 88%, 69%, 80%, and 81%, respectively, in tofacitinib-treated subjects.

CONCLUSION: Achieving a PASI50 response after 8 weeks of treatment with tofacitinib in psoriasis patients appears to be a reliable predictor of achieving a PASI75 response at week 16.

TRIAL REGISTRATION: clinicaltrials.gov: NCT01276639 and NCT01309737.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalThe Journal of dermatological treatment
Volume28
Issue number1
Early online date18 Aug 2016
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Administration, Oral
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperidines
  • Psoriasis
  • Pyrimidines
  • Pyrroles
  • ROC Curve
  • Severity of Illness Index
  • Treatment Outcome
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial

Fingerprint

Dive into the research topics of 'Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis'. Together they form a unique fingerprint.

Cite this